TY - JOUR
T1 - Hematopoietic stem cell transplantation in Oman
AU - Dennison, D.
AU - Al Kindi, S.
AU - Pathare, A.
AU - Daar, S.
AU - Nusrat, N.
AU - Ur Rehman, J.
AU - Zia, F.
AU - Khan, H.
AU - Khan, M.
AU - Alghazaly, A.
AU - Al Zadjali, S.
AU - Tauro, M.
AU - Al Lawatia, A. T.
AU - Ganguly, S. S.
PY - 2008
Y1 - 2008
N2 - Hematopoietic SCT (HSCT) is an integral part of the management of patients with hematologic disorders. The Sultanate of Oman, with a population of 2.3 million, has an HSCT program based in the Sultan Qaboos University (SQU) hospital. Initiated in 1995, this two-bed unit continues to be the only program in the country. Between June 1995 and August 2006, a total of 128 patients underwent HSCT in this center, averaging about 10-12 transplants per year. The median age of these patients was 11 years (2 months to 45 years). Hematologic malignancies (49%) and inherited disorders (42%) constituted the major transplant indications, whereas BM failure accounted for the remaining. The majority of transplants carried out so far have been HLA-matched sibling-donor allogeneic HSCTs. Among the inherited disorders, homozygous beta-thalassemia and primary immunodeficiency are important transplant indications in this center. The approximate cost of an uncomplicated transplant in this center is US$50000. The success of this program has now led to the initiation of a new and larger HSCT complex to provide the opportunity for more patients to benefit from this treatment modality within the country.
AB - Hematopoietic SCT (HSCT) is an integral part of the management of patients with hematologic disorders. The Sultanate of Oman, with a population of 2.3 million, has an HSCT program based in the Sultan Qaboos University (SQU) hospital. Initiated in 1995, this two-bed unit continues to be the only program in the country. Between June 1995 and August 2006, a total of 128 patients underwent HSCT in this center, averaging about 10-12 transplants per year. The median age of these patients was 11 years (2 months to 45 years). Hematologic malignancies (49%) and inherited disorders (42%) constituted the major transplant indications, whereas BM failure accounted for the remaining. The majority of transplants carried out so far have been HLA-matched sibling-donor allogeneic HSCTs. Among the inherited disorders, homozygous beta-thalassemia and primary immunodeficiency are important transplant indications in this center. The approximate cost of an uncomplicated transplant in this center is US$50000. The success of this program has now led to the initiation of a new and larger HSCT complex to provide the opportunity for more patients to benefit from this treatment modality within the country.
UR - http://www.scopus.com/inward/record.url?scp=50549102512&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=50549102512&partnerID=8YFLogxK
U2 - 10.1038/bmt.2008.131
DO - 10.1038/bmt.2008.131
M3 - Review article
C2 - 18724280
AN - SCOPUS:50549102512
SN - 0268-3369
VL - 42
SP - S109-S113
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - SUPPL.1
ER -